Langer Christof
Chief Executive Officer & Managing Director
Immunology
S-TARget therapeutics
Albania
Biography
Langer Christof received an international engineering degree in food- and biotechnology (MSc) from the Vienna University of A pplied Sciences in 1996. In the same year he started his professional career at Baxter BioScience where he held various leading positions in the area of pharmaceutical Management production. 2001 he was promoted to head of production in Vienna; in 2002 he was announced “Director Manufacturing”. In this role he successfully completed a 2 year training to become a Lean-Six-Sigma Black Belt. In 2004, he moved to the Czech Republic to start up and lead Baxter‘s newly built Czech vaccines entity Baxter s.r.o. as “Managing Director”. Starting in 2006, he took responsibility as “Managing Director” in Neuchatel, Switzerland, for Baxter’s blockbuster manufacturing facility Baxter BioScience sarl. After returning to Austria in 2009, he founded an operations & strategy consulting firm whilst preparing for the foundation of S-TARget therapeutics in 2010. Langer Christof received an international engineering degree in food- and biotechnology (MSc) from the Vienna University of A pplied Sciences in 1996. In the same year he started his professional career at Baxter BioScience where he held various leading positions in the area of pharmaceutical Management production. 2001 he was promoted to head of production in Vienna; in 2002 he was announced “Director Manufacturing”. In this role he successfully completed a 2 year training to become a Lean-Six-Sigma Black Belt. In 2004, he moved to the Czech Republic to start up and lead Baxter‘s newly built Czech vaccines entity Baxter s.r.o. as “Managing Director”. Starting in 2006, he took responsibility as “Managing Director” in Neuchatel, Switzerland, for Baxter’s blockbuster manufacturing facility Baxter BioScience sarl. After returning to Austria in 2009, he founded an operations & strategy consulting firm whilst preparing for the foundation of S-TARget therapeutics in 2010.
Research Interest
Immunology